The biggest change was that 25 (5.2%), 8 (1.6%), and 1 (0.2%) patients in the AML, NOS group according to the 4th WHO, were re-classified into the AML-MR, KMT2A rearrangement, and NUP98 rearrangement subgroups, respectively. This evidence concerns the gene NUP98 and acute myeloid leukemia.